Literature DB >> 17931588

Bioluminescence immunoassay for angiotensin II using aequorin as a label.

Xiaoge Qu1, Sapna K Deo, Emre Dikici, Mark Ensor, Michael Poon, Sylvia Daunert.   

Abstract

Angiotensin II is a biologically active component of the renin-angiotensin system. High levels of angiotensin II may be responsible for hypertension and heart failure because they increase systemic vascular resistance, arterial pressure, and sodium and fluid retention. Therefore, it is important to monitor angiotensin II levels for the treatment of hypertension and heart diseases. The goal of this work was to develop a bioluminescence immunoassay using aequorin as a label to measure angiotensin II levels in human plasma. This method utilizes a genetically engineered fusion protein between angiotensin II and aequorin. For that, the C terminus of angiotensin II was fused to the N terminus of apoaequorin using molecular biology techniques. A heterogeneous immunoassay was then developed for the determination of angiotensin II. A detection limit of 1 pg/mL was obtained with the optimized assay, allowing for the determination of angiotensin II at physiological levels in human plasma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17931588     DOI: 10.1016/j.ab.2007.08.038

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  2 in total

1.  Bioluminescence inhibition assay for the detection of hydroxylated polychlorinated biphenyls.

Authors:  Krystal Teasley Hamorsky; C Mark Ensor; Emre Dikici; Patrizia Pasini; Leonidas Bachas; Sylvia Daunert
Journal:  Anal Chem       Date:  2012-08-29       Impact factor: 6.986

2.  Red-Shifted Aequorin Variants Incorporating Non-Canonical Amino Acids: Applications in In Vivo Imaging.

Authors:  Kristen M Grinstead; Laura Rowe; Charles M Ensor; Smita Joel; Pirouz Daftarian; Emre Dikici; Jean-Marc Zingg; Sylvia Daunert
Journal:  PLoS One       Date:  2016-07-01       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.